Skip to content
Head to head

Sarepta Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: SRPT · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

SRPT -24.0%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
SRPTVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price13.33515.02
Change today-5.93%-1.08%
1-year return-19.1%+22.0%
Market cap$1.43B$130.58B
52-week range13.25 – 24.68412.27 – 568.67
Valuation
P/E (TTM)-10.3333.14
P/E percentile, own 5-yr range43rd99th
P/B0.936.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-7.1315.32
Net profit (TTM)$-764.59M$3.88B
Revenue (TTM)$1.96B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-4.5%+11.8%
Gross margin56.8%85.5%
Operating margin-0.4%33.1%
Net margin-5.9%30.7%
Free cash flow (TTM)$171.40M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership98.1%96.8%
Insider activity (12mo)26 buy / 24 sell28 buy / 22 sell
Short interest (% of float)18.3%1.9%
Analyst consensus20% buy / 53% hold / 27% sell (15)95% buy / 5% hold (21)
Analyst price target$22 (+68%)$624 (+21%)
StockVane view
StockVane Quant RatingD (21)C (68)
Company
Employees8356,400
Founded19801989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.